Jason Luke, MD, FACP, FASCO
@jasonlukemd
Followers
6K
Following
5K
Media
482
Statuses
7K
Physician-Scientist-Executive & Chief Medical Officer @StrandTx
Joined March 2015
Catch us at #JPM26, where Strand Therapeutics CEO @DrSynbio will be presenting on Wednesday, January 14, 2026, at 10:30 AM PT. Looking forward to connecting with innovators and industry leaders in San Francisco. More information: https://t.co/6yLeagRGim
0
2
8
“We are standing on the precipice of the future of genetic medicines.” Strand Therapeutics CEO @DrSynbio joined @ashleevance on @corememory to share how Strand is building mRNA therapeutics that sense their environment and activate only in target cells, like cancer. Learn how
corememory.com
Strand Therapeutics and the next era of mRNA
0
5
11
Excited to share that Jeb Keiper (@JebKeiper) former CEO of Nimbus, is joining the Strand Therapeutics Board of Directors. I have known Jeb for years and always saw him as the ideal independent board member. Visionary. Grounded. Builder. Operator.
We're excited to welcome @JebKeiper to Strand's Board as an independent Director! Strand gains invaluable expertise from Jeb, whose proven track record as former CEO of Nimbus Therapeutics encompasses preclinical R&D innovation, clinical development, and global business
2
2
17
We're excited to welcome @JebKeiper to Strand's Board as an independent Director! Strand gains invaluable expertise from Jeb, whose proven track record as former CEO of Nimbus Therapeutics encompasses preclinical R&D innovation, clinical development, and global business
1
3
9
China biotech landscape update from Jefferies. Unprecedented level of activity and R&D productivity, only question is what the industry is going to do with so many interchangeable programs.
6
47
234
What drives pathogenic B-cell activation in certain #autoimmune diseases and #cancers? Benjamin E. Gewurz @BenGewurz & team @BrighamsWomens discover stimulation of B cells with common pathogenic triggers strongly induces BCAT1, which localized to lysosomal membranes to support
0
1
15
Online Now: A longitudinal single-cell atlas to predict outcome and toxicity after BCMA-directed CAR T cell therapy in multiple myeloma https://t.co/9ZtF98E39Z
1
30
89
Atlas Venture 2025 Year In Review https://t.co/qoUKkkAeAS Been a tough year to pin down as we went from bearish spring to bullish yea end… Listening at 1.25x+ speed is definitely recommended, and moves through the nearly 50-minute presentation slightly faster.
lifescivc.com
This year has truly been a rollercoaster! The markets started off with optimism, but then collapsed into the spring, only to rebound with enthusiasm in recent months. The cadence of M&A has picked...
7
26
181
Tx @sciam for quote on mRNA therapies! @StrandTx is leading the field developing off-the-shelf RNA Rx w impact in oncology & beyond. Excitement for pharmacy ready, as well as personalized RNA modalities is a rising tide for all aspects of biomedicine!
scientificamerican.com
Vaccines based on mRNA can be tailored to target a cancer patient’s unique tumor mutations. But crumbling support for cancer and mRNA vaccine research has endangered this promising therapy
0
1
2
Time/cost to human PoC and pre-clinical predictability of success are the two largest areas needed for radical advancement. 1) regulatory reform: we need to get new therapies to patients, faster and cheaper. 2) more data: we need to open the books on clinical science, +/-
This post is also an argument for why AI won't bail us out of regulatory reform to make in-human testing easier. In fact, in-human data from trials would be the best complement to AI and one way to avoid the "slop trap" by training it on meaningful results.
2
3
29
So excited for our work advancing RNA therapeutics @StrandTx & to see everyone tonight #SITC25 40th Annual Mtg Party #Checkpoints are ready to rock at the best party of the year! All funds raised go to the @sitcancer Forward Fund to support early career researchers. Be there!!!
Excited our @StrandTx musician CMO @jasonlukemd is being awarded as a “Champion of @sitcancer" #SITC25 & playing trumpet in the Checkpoints band! Our team is excited to rock next gen #immunotherapy advances with multiple field leading, novel treatments for #cancer!
0
2
18
We’re honored to announce that Strand Therapeutics has been awarded the BioTech Startup of the Year award from BioTech Breakthrough! Thanks to the team at BioTech Breakthrough for highlighting the dedication of our team as we continue to forge a new path in mRNA therapeutics!
0
3
9
Super excited to be @sitcancer #SITC25! On-going insightful BoD mtg where it’s great seeing & discussing the future of the society & cancer #immunotherapy. Hope to see all of the IO community this weekend!
This week @StrandTx CMO @jasonlukemd is leading the @sitcancer 40th Annual Meeting! He will be voting on the Board of Directors, Lecturing on the future of TCR therapeutics & Chairing a session on late breaking clinical abstracts. More information here: https://t.co/ox1eNubHJs
2
1
15
At @StrandTx we were honored for #PrixGalien Best Start Up nomination. Tx organizers & congrats to winners! We hope to return but now back to novel RNA therapeutics for patients facing cancer & other dz! @TasukuKitada
1
4
17
Colleague Prof. Max Konig and Hopkins colleagues shows that anti-9G4 precision cellular therapies provide a strategy to selectively target pathogenic B cells in lupus, while minimizing risks of infection and cytokine-related toxicities. Read more here: https://t.co/v9kKkdXFR4
1
15
75
🚨Our new paper is out today in Nature! We show that SARS-CoV-2 mRNA vaccines can sensitize tumors to immune checkpoint blockade (ICI) — revealing that clinically available RNA vaccines may act as potent immune modulators.
nature.com
Nature - mRNA vaccines targeting SARS-CoV-2 also sensitize tumours to immune checkpoint inhibitors.
28
70
217
🧬 In-Vivo CAR-T: Pharma’s New Holy Grail Ex-vivo cell therapy was biotech’s moonshot. But it’s running into gravity, manufacturing drag, cost friction, and clinical complexity. The next frontier is in-vivo CAR-T, programming immune cells directly inside the body. Pharma’s
6
70
242
Thank you to all who engaged on my blog trifecta on my two decade “Atlas-versary”…. They were fun and cathartic to write, and hopefully of broader interest. ICYMI - here are the links to the three posts: The science of startups: risk, novelty, innovation:
lifescivc.com
In the blink of an eye, twenty years have passed: in mid-October 2005, I joined Atlas Venture as a principal on the global life science team. We closed Fund VII a few months after I joined; and,...
3
9
131
Great Elpiscience SAB & honored to speak at Immunology Innovations hosted by Westlake University, Hangzhou, CN. Tremendous op to network on @StrandTx LNP repRNA IL-12 cancer IO programs & in vivo CART. Also lectured on p38i work w @RiyueSunnyBao. Beautiful place - tx for invite!
2
1
16